The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance

被引:38
|
作者
Goette, Matthias [1 ,2 ,3 ]
机构
[1] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada
[2] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada
[3] McGill Univ, Dept Med, Div Expt Med, Montreal, PQ H3A 1A3, Canada
基金
加拿大健康研究院;
关键词
HIV-1; REVERSE-TRANSCRIPTASE; CROSS-RESISTANCE; MUTATIONAL BIAS; NS5A INHIBITOR; VIRUS; PROTEASE; FIDELITY; REPLICATION; INFECTION; VARIANTS;
D O I
10.1016/j.coviro.2012.08.004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The selection of resistance to antiviral drugs depends on multiple parameters, including the genetic barrier that is often broadly defined as the number of mutations required to overcome drug selective pressure. In this review, it is intended to assess the roles of genetic barrier and viral fitness at various stages of the selection process. Several examples in the fields of HIV and HCV drug resistance show that the two parameters are distinct and independent. An analogy to the concept of kinetic versus thermodynamic control of chemical reactions supports a more narrow definition of the genetic barrier as the kinetic obstacle for the generation of genetic changes required to overcome selective pressure.
引用
收藏
页码:644 / 650
页数:7
相关论文
共 50 条
  • [31] Antiviral drug discovery and development
    Burger, David M.
    NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (12) : 1019 - 1019
  • [32] Perspectives on antiviral drug development
    Wainberg, Mark A.
    ANTIVIRAL RESEARCH, 2009, 81 (01) : 1 - 5
  • [33] APPROACHES TO ANTIVIRAL DRUG DEVELOPMENT
    PRUSOFF, WH
    LIN, TS
    AUGUST, EM
    WOOD, TG
    MARONGIU, ME
    YALE JOURNAL OF BIOLOGY AND MEDICINE, 1989, 62 (02): : 215 - 225
  • [34] Surrogacy in antiviral drug development
    Shaunak, S
    Davies, DS
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (01) : 75 - 80
  • [35] Antiviral drug development Foreword
    Field, Hugh J.
    Wainberg, Mark A.
    FUTURE VIROLOGY, 2011, 6 (05) : 545 - 547
  • [36] LEXITROPSINS IN ANTIVIRAL DRUG DEVELOPMENT
    LOWN, JW
    ANTIVIRAL RESEARCH, 1992, 17 (03) : 179 - 196
  • [37] Antiviral drug discovery and development
    Nature Reviews Drug Discovery, 2007, 6 : 1019 - 1019
  • [38] DEVELOPMENT OF RESISTANCE TO ANTIVIRAL DRUGS
    RENIS, HE
    BUTHALA, DA
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1965, 130 (A1) : 343 - +
  • [39] Mutational fitness landscape and drug resistance
    Flynn, Julia
    Samant, Neha
    Schneider-Nachum, Gily
    Tenzin, Tsepal
    Bolon, Daniel N. A.
    CURRENT OPINION IN STRUCTURAL BIOLOGY, 2023, 78
  • [40] Genetic Barrier to Resistance for Dolutegravir
    Llibre, Josep M.
    Pulido, Federico
    Garcia, Federico
    Garcia Deltoro, Miguel
    Blanco, Jose L.
    Delgado, Rafael
    AIDS REVIEWS, 2015, 17 (01) : 56 - 64